Evidence map›Paper›PMID 30153085›Full record

Trial reportOphthalmic epidemiology2019

A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.

Daniel P Morberg, Wondu Alemayehu, Muluken Melese, Takele Lakew, Alemayehu Sisay, Zhaoxia Zhou, Vicky Cevallos, Catherine E Oldenburg, Travis C Porco, Thomas M Lietman and 1 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmic epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Antibiotics for trachoma.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Daniel P Morberga Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Wondu Alemayehub Orbis International , Addis Ababa , Ethiopia.
Muluken Meleseb Orbis International , Addis Ababa , Ethiopia.
Takele Lakewb Orbis International , Addis Ababa , Ethiopia.
Alemayehu Sisayb Orbis International , Addis Ababa , Ethiopia.
Zhaoxia Zhoua Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Vicky Cevallosa Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Catherine E Oldenburga Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Travis C Porcoa Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Thomas M Lietmana Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
Jeremy D Keenana Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
International Trachoma Initiative · ETSan Francisco Foundation · USUniversity of California, San Francisco · USGlobal Brain Health Institute · US

Funding

TANA IIU10EY016214 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M · 2004 to 2013
$4.4M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
Forecasting Trachoma Control - Diversity SupplementR01EY025350 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Travis Christian Porco · 2016 to 2026
$3.3M
Sanitation, Water, and Instruction in Face-washing for TrachomaU10EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2014 to 2018
$2.7M
NEI NIH HHS R01 EY025350NEI NIH HHS U10 EY016214NEI NIH HHS U10 EY023939NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundMass azithromycin distributions are effective for clearing ocular strains of Chlamydia trachomatis, yet infection frequently returns in areas with hyperendemic trachoma. A better understanding of the factors associated with chlamydial reinfection could be helpful to plan trachoma elimination strategies.

methodsThis was a prospective cohort study conducted in a trachoma-hyperendemic region of Ethiopia in 2003. As part of a larger cluster-randomized trial, 21 villages were treated with a single mass azithromycin distribution and all children 5 years and younger were monitored for ocular chlamydia and clinically active trachoma at baseline and at 2 and 6 months following the treatment.

resultsIn 20 villages with available data, azithromycin treatment coverage was 88.7% (95% confidence interval [CI] 85.7-91.8%). In total, 1005 children tested negative for ocular chlamydia at the 2-month visit, of whom 41 became infected by 6 months (1.0 incident chlamydia infections per 100 person-months, 95%CI 0.7-1.4). The presence of intense trachomatous inflammation (TI) at baseline was associated with incident infection at 6 months (incidence rate ratio 1.91, 95%CI 1.03-3.55). Ocular chlamydia infections clustered more within households than communities: (intraclass correlation coefficient 0.01 for communities and 0.29 for households six months posttreatment). Younger children were more likely to have persistent clinically active trachoma (P = 0.03).

conclusionsMore intensive antibiotic distributions may be warranted for younger children, for children with TI, and for households containing children with ocular chlamydia infections.

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisAzithromycinChild, PreschoolChlamydia trachomatisEthiopiaEye Infections, BacterialFemaleFollow-Up StudiesHumansIncidenceInfantMaleProspective StudiesRisk FactorsRural PopulationAnti-Bacterial AgentsAzithromycinchlamydia trachomatisincidencerisk factorsTrachoma

Identifiers

PMID30153085
PMCPMC6344262
OpenAlexW2889093686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.